SCHEMBL3525522

SCHEMBL3525522

Nc1nccc2occ(-c3ccc(NC(=O)NC4CCCC4)cc3)c12

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 0.66
KIT P10721 4/20 0.53
FLT3 P36888 2/20 0.53
PDGFRA P16234 3/20 0.52
EPHX1 P07099 5/20 0.50
RAB9A P51151 5/20 0.50
GAA P10253 1/20 0.50
TEK Q02763 1/20 0.49
PLK4 O00444 1/20 0.47
MAPK13 O15264 1/20 0.47
DYRK3 O43781 1/20 0.47
ROCK2 O75116 1/20 0.47
MAP4K4 O95819 1/20 0.47
NTRK1 P04629 1/20 0.47
LCK P06239 1/20 0.47
CDK1 P06493 1/20 0.47
CSF1R P07333 1/20 0.47
LYN P07948 1/20 0.47
RET P07949 1/20 0.47
FER P16591 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525515 0.79 KDR (1.00) KDRKITFLT3PLK4ROCK2
SCHEMBL3534578 0.79 KDR (0.64) KDRKITFLT3TEKPLK4
SCHEMBL3525709 0.79 RIPK1 (0.60) KDRKITFLT3PDGFRATEK
SCHEMBL3532197 0.78 KDR (1.00) KDRKITFLT3PLK4ROCK2
SCHEMBL3530426 0.77 FLT1 (0.71) KDRKITFLT3PDGFRARAB9A
SCHEMBL3529762 0.76 KDR (0.72) KDRKITFLT3PDGFRATEK
SCHEMBL3531509 0.76 RIPK1 (0.72) KDRKITFLT3PDGFRATEK
SCHEMBL3529664 0.76 KDR (0.57) KDRKITFLT3RAB9ATEK
SCHEMBL3525546 0.74 KDR (0.50) KDRKITFLT3TEKPLK4
SCHEMBL3531290 0.74 KDR (0.68) KDRKITFLT3PDGFRATEK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885KIT 188/4885FLT3 25/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885KIT 188/4885FLT3 25/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885KIT 188/4885FLT3 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.